{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:00:52Z","timestamp":1747166452652,"version":"3.40.5"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jvacx.2023.100401","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:44:39Z","timestamp":1698407079000},"page":"100401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC\u00ae) in healthy adults aged 18\u201355\u00a0years: Randomized, double-blind, placebo-controlled, phase I clinical trial"],"prefix":"10.1016","volume":"15","author":[{"given":"Akram","family":"Ansarifar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin Hamidi","family":"Farahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Karimi","family":"Rahjerdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Ahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-5768","authenticated-orcid":false,"given":"Ali","family":"Sheidaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiya","family":"Gohari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pouria","family":"Basiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2584-458X","authenticated-orcid":false,"given":"Milad","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Jahangiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosar","family":"Naderi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheil","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pezhman","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Honari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samane","family":"Khodaverdloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Shooshtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajar Mehr","family":"Azin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohrab","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Batool","family":"Shafaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Allahyari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arina","family":"Monazah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Khodaei","family":"Poor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman","family":"Bakhshande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Taghva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Karimi","family":"Nia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud Solaymani","family":"Dodaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7293-1889","authenticated-orcid":false,"given":"Mohsen","family":"Foroughizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2023.100401_b0005","unstructured":"Organization WH. COVID-19 vaccine tracker and landscape; 2023. Available from: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"issue":"10","key":"10.1016\/j.jvacx.2023.100401_b0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100401_b0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"J American Med Assoc"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100401_b0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100401_b0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J Global Infect Dis"},{"issue":"25","key":"10.1016\/j.jvacx.2023.100401_b0030","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.vaccine.2014.03.078","article-title":"How advances in immunology provide insight into improving vaccine efficacy","volume":"32","author":"Slifka","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100401_b0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann Med"},{"key":"10.1016\/j.jvacx.2023.100401_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: from whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"13\u201314","key":"10.1016\/j.jvacx.2023.100401_b0045","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0264-410X(98)00416-2","article-title":"New technologies for making vaccines","volume":"17","author":"Ellis","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2023.100401_b0050","first-page":"2410","article-title":"Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines","author":"Flanagan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvacx.2023.100401_b0055","unstructured":"WHO. Draft landscape of COVID-19 candidate vaccines; Jan 15, 2021. Available from: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"issue":"11","key":"10.1016\/j.jvacx.2023.100401_b0060","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/vaccines9111271","article-title":"Development of Inactivated FAKHRAVAC\u00ae Vaccine against SARS-CoV-2 Virus: Preclinical Study in Animal Models","volume":"9","author":"Ghasemi","year":"2021","journal-title":"Vaccines"},{"year":"2010","series-title":"Statistics in clinical vaccine trials","author":"Nauta","key":"10.1016\/j.jvacx.2023.100401_b0065"},{"issue":"6","key":"10.1016\/j.jvacx.2023.100401_b0070","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jvacx.2023.100401_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101078","volume":"39","author":"Zakarya","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jvacx.2023.100401_b0080","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","author":"Polack","year":"2020","journal-title":"New England J Med"},{"issue":"25","key":"10.1016\/j.jvacx.2023.100401_b0085","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"New England J Med"},{"issue":"10240","key":"10.1016\/j.jvacx.2023.100401_b0090","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jvacx.2023.100401_b0095","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26. COV2. S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"New England J Med"},{"issue":"10","key":"10.1016\/j.jvacx.2023.100401_b0100","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"J American Med Assoc"},{"key":"10.1016\/j.jvacx.2023.100401_b0105","series-title":"Protein Chromatography","first-page":"439","article-title":"Fast protein liquid chromatography","author":"Madadlou","year":"2011"},{"key":"10.1016\/j.jvacx.2023.100401_b0110","series-title":"Protein purification protocols","first-page":"253","article-title":"Fast protein liquid chromatography","author":"Sheehan","year":"2004"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223001420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223001420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T07:13:54Z","timestamp":1719990834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136223001420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":22,"alternative-id":["S2590136223001420"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100401","relation":{},"ISSN":["2590-1362"],"issn-type":[{"type":"print","value":"2590-1362"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC\u00ae) in healthy adults aged 18\u201355\u00a0years: Randomized, double-blind, placebo-controlled, phase I clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100401"}}